NEW YORK and SOMERSET, N.J. (PRWEB) June 17, 2019 IVERIC bio, Inc. (NASDAQ: ISEE) and Catalent Biologics, today announced that they have entered into an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) vector for IVERIC bio’s gene therapy product candidates…

Source link